Clinical Trials Browser

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

NCT03860844 2025-09-09

ISAKIDS

Phase 2 Terminated

67 enrolled 25 charts

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02990338 2025-01-17

ICARIA-MM

Phase 3 Completed

307 enrolled 32 charts 2 FDA

Plasma cell

Multiple Myeloma

NCT03194867 2024-06-14

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Phase 1/2 Completed

109 enrolled 27 charts

Plasma cell

Multiple Myeloma

NCT03637764 2023-07-10

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Phase 1/2 Terminated

107 enrolled 30 charts

Tumor-Agnostic

Neoplasms

NCT03367819 2022-05-16

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Phase 1/2 Terminated

44 enrolled 24 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

NCT02999633 2022-03-21

ISLAY

Phase 2 Terminated

14 enrolled 7 charts

LymphoidOther hematologic neoplasm

Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

IKEMA

KRDI in Transplant-Eligible MM

A Study of Isatuximab-based Therapy in Participants With Lymphoma

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis